Uncategorized
InSite Vision terminates QLT bid, plans to merge with Sun Pharma
InSite Vision terminated a merger agreement with QLT and accepted a merger bid from Sun Pharmaceutical.The all-cash acquisition is valued at $0.35 per share, or approximately $48 million in aggregate equity value, on a fully diluted basis, according to a press release from InSite.